Research and Markets: Australia Pharmaceuticals and Healthcare Report Q1 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/28e37c/australia_pharmace) has announced the addition of the "Australia Pharmaceuticals and Healthcare Report Q1 2011" report to their offering.

Australia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Australia's pharmaceuticals and healthcare industry.

The outlook for Australia’s pharmaceutical market is challenging. Combined sales of prescription drugs and over-the-counter (OTC) medicines in Australia are forecast to decrease from AUD10.02bn (US$7.95bn) in 2009 to AUD9.30bn (US$7.48bn) in 2014, primarily as a result of the patent cliff. Since the last update of BMI’s Pharmaceuticals & Healthcare Report, they have significantly downgraded their forecast for pharmaceutical sales in Australia.

Like many developed states, Australia is looking to constrain healthcare expenditure, particularly medicine spending. In October 2010, the lower house of parliament passed the National Health Amendment Pharmaceutical Benefits Scheme Bill 2010. Health Minister Nicola Roxon said the changes to the Pharmaceutical Benefits Scheme (PBS) will result in lower-cost medicines through increased pricing transparency by pharmaceutical suppliers.

Key Topics Covered:

  • Executive Summary
  • SWOT Analysis
  • Australia Pharmaceuticals And Healthcare Industry SWOT
  • Australia Political SWOT
  • Australia Economic SWOT
  • Australia Business Environment SWOT
  • Pharmaceutical Business Environment Ratings
  • Tables

Companies Mentioned:

  • Sigma,
  • Australian Pharmaceutical Industries,
  • Alphapharm,
  • Herron Pharmaceuticals,
  • CSL,
  • Mayne (Hospira),
  • Sanofi-Aventis,
  • GlaxoSmithKline,
  • Merck & Co, Novartis

For more information visit http://www.researchandmarkets.com/research/28e37c/australia_pharmace



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Australia  Australia/Oceania

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.